Calvin Sandra (CIK 1882909) reported 20 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-09-17). Recent activity: Buy TVTX (2,500 shares), Buy TVTX (1,250 shares), Buy TVTX (1,625 shares), Sell TVTX (4,275 shares), Sell TVTX (800 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 2,500 | $68,750 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 1,250 | $28,000 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 1,625 | $33,248 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 4,275 | $265,627 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 800 | $50,278 |
| 2026-09-17 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 300 | $19,099 |
| 2026-04-16 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 2,500 | $56,000 |
| 2026-04-16 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 6,250 | $55,812 |
| 2026-04-16 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 6,500 | $132,990 |
| 2026-04-16 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 21,977 | $902,595 |
| 2026-02-03 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 15,180 | $0 |
| 2026-02-03 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 4,333 | $139,176 |
| 2025-12-29 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 7,402 | $296,080 |
| 2025-12-16 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 2,910 | $104,760 |
| 2025-11-06 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 10,000 | $252,500 |
| 2025-11-06 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 17,500 | $470,400 |
| 2025-11-06 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 15,000 | $412,500 |
| 2025-11-06 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 12,500 | $280,000 |
| 2025-11-06 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Buy | 6,250 | $55,812 |
| 2025-11-06 | Travere Therapeutics, Inc. (TVTX) | SVP, CHIEF ACCOUNTING OFFICER | Sell | 67,115 | $2.4M |
来源：SEC Form 4 申报文件 · 截至 2026-09-17